Private company

Kinnate Biopharma Inc.

In its 2024 annual report the company says: “We are a clinical-stage precision oncology company that has focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.”3 It is headquartered in San Diego, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address11975 El Camino Real, Ste 101, San Diego, Ca 921302
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage precision oncology company that has focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456-$121.2M in 2023+237% since 2020
-$150.0M-$100.0M-$50.0M02020: -$36.0M-$36.0M20202021: -$90.1M-$90.1M2021+150%2022: -$118.5M-$118.5M2022+32%2023: -$121.2M-$121.2M2023+2%
Net income456-$112.6M in 2023+215% since 2020
-$150.0M-$100.0M-$50.0M02020: -$35.8M-$35.8M20202021: -$89.8M-$89.8M2021+151%2022: -$116.3M-$116.3M2022+30%2023: -$112.6M-$112.6M2023−3%
Fiscal year201920202021202220232024
Research and development$29.2M4$67.2M5$88.2M6$90.8M6
Operating expenses$90.1M5$118.5M6$121.2M6
Operating income-$36.0M4-$90.1M5-$118.5M6-$121.2M6
Income tax$04$05$06$06
Net income-$35.8M4-$89.8M5-$116.3M6-$112.6M6
Earnings per share-$5.284-$2.065-$2.646-$2.426
Earnings per share (diluted)-$5.284-$2.065-$2.646-$2.426
Shares (weighted, basic)43.6M shares544.1M shares646.6M shares6
Shares (weighted, diluted)43.6M shares544.1M shares646.6M shares6

Compare Kinnate Biopharma Inc. with another company

Corporate structure

Kinnate Biopharma Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Kinnate Biopharma Inc.

  • Vida Ventures, LLC Filed SC 13G/A on Kinnate Biopharma Inc., latest Nov 13, 2024 (3 filings since Feb 10, 2022)
  • Foresite Capital Fund V, L.P. Filed SC 13D/A on Kinnate Biopharma Inc., latest Apr 5, 2024 (4 filings since Nov 14, 2023)
  • ORBIMED ADVISORS LLC Filed SC 13D/A on Kinnate Biopharma Inc., latest Feb 21, 2024 (6 filings since Feb 23, 2023)
  • Lynx1 Capital Management LP Filed SC 13G/A on Kinnate Biopharma Inc., latest Feb 14, 2024 (2 filings since Jan 23, 2023)
  • Nextech V Oncology S.C.S., SICAV-SIF Filed SC 13G/A on Kinnate Biopharma Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • TANG CAPITAL PARTNERS LP Filed SC 13G/A on Kinnate Biopharma Inc., latest Feb 14, 2024 (2 filings since Nov 27, 2023)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on Kinnate Biopharma Inc., latest Aug 14, 2023 (3 filings since Feb 14, 2022)
  • Foresite Capital Fund IV, L.P. Filed SC 13D/A on Kinnate Biopharma Inc., latest May 10, 2023 (2 filings since Feb 22, 2023)
  • FMR LLC Filed SC 13G/A on Kinnate Biopharma Inc., latest Feb 9, 2022
  • Kinnate Biopharma Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Kinnate Biopharma Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.8M6 Dec 31, 2023$3.8M6 Dec 31, 20220%
Accumulated depreciation$1.5M6 Dec 31, 2023$741.0K6 Dec 31, 2022+107.8%
Property and equipment, net$2.3M6 Dec 31, 2023$3.1M6 Dec 31, 2022−26.0%
Operating-lease assets (leased space)$2.5M6 Dec 31, 2023$3.4M6 Dec 31, 2022−26.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$57.0M6 Dec 31, 2023$29.3M6 Dec 31, 2022+94.8%
Marketable securities, current$97.0M6 Dec 31, 2023$172.2M6 Dec 31, 2022−43.7%
Long-term investments$10.3M6 Dec 31, 2023$39.1M6 Dec 31, 2022−73.8%

Leadership

Who has led Kinnate Biopharma Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nima Farzan2020–2024

President

  1. Nima Farzan2020

Chief financial officer

  1. Neha Krishnamohan2021–2024

Chief operating officer

  1. Mark A. Meltz2020–2024
2025
Board members and other officers (11)

Timeline

  1. Apr 3, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights21
  2. Mar 1, 20248-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure22
  3. Feb 16, 20248-K Entered a material agreement; Regulation FD disclosure23
  4. Jan 16, 20248-K Regulation FD disclosure24
  5. Nov 22, 20238-K Executive or director change25
  6. Nov 15, 20238-K Other events26
  7. Nov 9, 20238-K Results of operations27
  8. Sep 18, 20238-K Results of operations; Exit or restructuring costs; Regulation FD disclosure28
  9. Aug 8, 20238-K Results of operations29
  10. Jul 28, 20238-K Bylaws or fiscal year changed30
  11. Jun 12, 20238-K Shareholder vote31
  12. May 11, 20238-K Results of operations32
  13. Dec 2, 2020New chief executive Nima Farzan becomes CEO9

Calendar

When it reported results

  1. Nov 9, 2023Reported quarterly or annual results27
  2. Sep 18, 2023Reported quarterly or annual results28
  3. Aug 8, 2023Reported quarterly or annual results29
  4. May 11, 2023Reported quarterly or annual results32
  5. Apr 17, 2023Reported quarterly or annual results33
  6. Mar 15, 2023Reported quarterly or annual results34
  7. Nov 10, 2022Reported quarterly or annual results35
  8. Oct 11, 2022Reported quarterly or annual results36

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

159 filings to the SEC since October 2021: 4 annual reports, 7 quarterly reports, 27 major events, 74 insider forms, 25 large holders, 22 other. The latest 20:

  1. Nov 13, 2024SC 13G/A EDGAR
  2. Apr 17, 202415-12G EDGAR
  3. Apr 5, 20244 EDGAR
  4. Apr 5, 20244 EDGAR
  5. Apr 5, 20244 EDGAR
  6. Apr 5, 20244 EDGAR
  7. Apr 5, 20244 EDGAR
  8. Apr 5, 20244 EDGAR
  9. Apr 5, 20244 EDGAR
  10. Apr 5, 20244 EDGAR
  11. Apr 5, 20244 EDGAR
  12. Apr 5, 20244 EDGAR
  13. Apr 5, 20244 EDGAR
  14. Apr 5, 20244 OWNERSHIP DOCUMENT EDGAR
  15. Apr 5, 2024SC 13D/A AMENDMENT NO. 6 EDGAR
  16. Apr 5, 20244 EDGAR
  17. Apr 5, 20244 EDGAR
  18. Apr 3, 2024S-8 POS EDGAR
  19. Apr 3, 2024S-8 POS EDGAR
  20. Apr 3, 2024S-8 POS EDGAR

The 159 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

20 open-market trades by officers, directors and large owners since October 2021: 20 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 8, 2023Tananbaum James B.DirectorBuy1,780,000$2.80$5.0MForm 4
May 8, 2023Foresite Capital Management IV, LLC10% ownerBuy1,780,000$2.80$5.0MForm 4
May 5, 2023ORBIMED ADVISORS LLCDirectorBuy981,023$2.82$2.8MForm 4
May 5, 2023GORDON CARL LDirectorBuy981,023$2.82$2.8MForm 4
May 4, 2023ORBIMED ADVISORS LLCDirectorBuy479,909$2.75$1.3MForm 4
May 4, 2023GORDON CARL LDirectorBuy479,909$2.75$1.3MForm 4
May 2, 2023GORDON CARL LDirectorBuy338,262$2.67$903.2KForm 4
May 2, 2023OrbiMed Capital GP VII LLCDirectorBuy338,262$2.67$903.2KForm 4
May 1, 2023GORDON CARL LDirectorBuy716,157$2.62$1.9MForm 4
May 1, 2023OrbiMed Capital GP VII LLCDirectorBuy716,157$2.62$1.9MForm 4
Apr 28, 2023GORDON CARL LDirectorBuy350,749$2.55$894.4KForm 4
Apr 28, 2023OrbiMed Capital GP VII LLCDirectorBuy350,749$2.55$894.4KForm 4
Mar 14, 2022Williams Richard ThomasCHIEF MEDICAL OFFICERBuy25,000$8.37$209.2KForm 4
Mar 11, 2022Williams Richard ThomasCHIEF MEDICAL OFFICERBuy15,000$8.64$129.6KForm 4
Feb 15, 2022GORDON CARL LDirectorBuy9,000$9.96$89.6KForm 4
Feb 15, 2022OrbiMed Genesis GP LLCDirectorBuy9,000$9.96$89.6KForm 4
Feb 14, 2022GORDON CARL LDirectorBuy30,700$9.95$305.5KForm 4
Feb 14, 2022OrbiMed Genesis GP LLCDirectorBuy30,700$9.95$305.5KForm 4
Feb 11, 2022GORDON CARL LDirectorBuy156,000$10.22$1.6MForm 4
Feb 11, 2022OrbiMed Genesis GP LLCDirectorBuy156,000$10.22$1.6MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Kinnate Biopharma Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKinnate Biopharma Inc.1
  • CIK0001797768
  • Employer ID (EIN)82-45665261
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address11975 El Camino Real, Ste 101, San Diego, CA 921301
  • Phone85829946991
  • Shares outstanding47,225,312 as of Mar 20, 20246
  • Public float$76.0M as of Jun 30, 20236
  • On EDGAR sinceDec 23, 20191
  • Filings250 in all: 4 (92), 8-K (35), 3 (18), SC 13D/A (12), SC 13G/A (12), 10-Q (9), SC 13G (7), CORRESP (6)1
    All 41 form types

    UPLOAD (5), 10-K (4), DEF 14A (3), DEFA14A (3), S-8 (3), S-8 POS (3), SC 14D9/A (3), D (2), DRS/A (2), DRSLTR (2), EFFECT (2), POSASR (2), S-1/A (2), SC 13D (2), SC TO-T/A (2), SC14D9C (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 4/A (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), D/A (1), DRS (1), POS AM (1), S-1 (1), S-1MEF (1), S-3ASR (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2024
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Apr 3, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45